id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2028-0007,FDA,FDA-2022-E-2028,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-18T05:00:00Z,2024,12,2024-12-18T05:00:00Z,,2024-12-18T19:00:26Z,,0,0,090000648687bfaf
FDA-2022-E-2028-0006,FDA,FDA-2022-E-2028,Letter from U. S. Patent and Trademark Office,Other,Letter(s),2024-03-06T05:00:00Z,2024,3,2024-03-06T05:00:00Z,,2024-03-06T18:50:34Z,,0,0,09000064863f499c
FDA-2022-E-2028-0005,FDA,FDA-2022-E-2028,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2023-12-04T05:00:00Z,2023,12,2023-12-04T05:00:00Z,,2023-12-04T16:59:41Z,,0,0,09000064862d463f
FDA-2022-E-2028-0004,FDA,FDA-2022-E-2028,Determination of Regulatory Review Period for Purposes of Patent Extension; Qelbree,Notice,Determinations,2023-11-30T05:00:00Z,2023,11,2023-11-30T05:00:00Z,2024-05-29T03:59:59Z,2023-11-30T17:07:32Z,2023-26301,0,0,09000064862c32de
FDA-2022-E-2028-0003,FDA,FDA-2022-E-2028,Letter to U S Patent and Trademark Office,Other,Letter(s),2022-09-13T04:00:00Z,2022,9,2022-09-13T04:00:00Z,,2022-09-13T16:55:24Z,,0,0,09000064852f952c
FDA-2022-E-2028-0001,FDA,FDA-2022-E-2028,"Patent Extension Application from Foley & Lardner LLP on behalf of  Supernus Pharmaceuticals, Inc.",Other,Application,2022-08-26T04:00:00Z,2022,8,2022-08-26T04:00:00Z,,2022-08-26T14:48:38Z,,0,0,090000648527589c
FDA-2022-E-2028-0002,FDA,FDA-2022-E-2028,Cover Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-08-26T04:00:00Z,2022,8,2022-08-26T04:00:00Z,,2022-08-26T14:49:43Z,,0,0,090000648527589e